Time filter

Source Type

Sharma V.,Government Model Science College
Russian Journal of Herpetology | Year: 2014

The distribution of Elachistodon westermanni, Indian Egg Eater is expanded by adding of two more localities in currently known distribution. Occurrence in Punjab extends its northernmost point with first record for the state. © 2014 Folium Publishing Company. Source

Agrawal R.,Government Model Science College
Current Drug Targets | Year: 2014

The new chemical entity (NCE) has been knocked as novel antidiabetic agent, e.g. Saroglitazar. Saroglitazar is a drug for the treatment of Type II diabetes. Saroglitazar is marketed under the trade name Lipaglyn, developed by the Zydus Cadila. Lipaglyn is the first indigenously developed NCE by any Indian pharmaceutical company, ever. Lipaglyn has been approved for the treatment of Type II diabetes by the Drug Controller General of India in June 2013. Lipaglyn is indicated for the patients suffering from diabetes dyslipidemia. It also provides the option of a once-daily oral therapy. Saroglitazar regulates the lipid parameters as well as glycemic control. The present article describes Saroglitazar with its chemical synthesis and patent status with its summary of clinical studies. © 2014 Bentham Science Publishers. Source

Tiwari R.K.,Government Model Science College | Sharma S.,Rayat Polytechnic College
Chinese Physics Letters | Year: 2011

We study the non existence of shear in locally rotationally symmetric Bianchi type-III string cosmological models with bulk viscosity and variable cosmological term A. Exact solutions of the field equations are obtained by assuming the conditions: the bulk viscosity is proportional to the expansion scalar, ξ ∝ θ, expansion scalar is proportional to shear scalar, θ ∝ σ, and Λ is proportional to the Hubble parameter. The coefficient of bulk viscosity is assumed to be a power function of mass density. The corresponding physical interpretations of the cosmological solutions are also discussed. © 2011 Chinese Physical Society and IOP Publishing Ltd. Source

Kumar S.,Jamia Hamdard University | Agrawal R.,Government Model Science College
Recent Patents on Anti-Cancer Drug Discovery | Year: 2014

Afatinib is a recently introduced new tyrosine kinase inhibitor, approved by the USFDA on July 12, 2013. Afatinib is marketed under the trade name Gilotrif and developed by Boehringer Ingelheim GmbH. It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations. Afatinib is a covalent, irreversible inhibitor of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and HER4. Chemically afatinib is a 4-anilinoquinazoline derivative, having an acrylamide warhead. Gilotrif is the formulation of Afatinib di-meleate salt. Presently, afatinib has been approved in the USA, the European Union, Taiwan and Mexico. In this review, we have summarized the chemical characterization of afatinib, its synthesis, patent status, marketed formulation, available crystalline form and current clinical trials. © 2014 Bentham Science Publishers. Source

Pandey S.K.,Government Model Science College
Indian Journal of Physics | Year: 2012

An extension of the theory of optical emission spectra due to exciton-exciton collisions (in bulk GaAs at nonzero temperatures) for GaAs/AlGaAs quantum well systems has been attempted to understand the physics associated with the optical spectra due to excitonic scattering processes in these novel systems. The four typical processes have been considered to give different spectral shape, peak position, and temperature dependence of the emission spectra. The intensity of emitted light in quantum well systems varies inversely to the square of temperature, whereas in case of bulk materials it simply decreases with the temperature. The results arrived at are purely qualitative in nature. © 2012 IACS. Source

Discover hidden collaborations